

# Wanbo Tai

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7116283/wanbo-tai-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30  
papers

2,250  
citations

19  
h-index

36  
g-index

36  
ext. papers

2,921  
ext. citations

9  
avg, IF

5.62  
L-index

#	Paper	IF	Citations
30	Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. <i>Cellular and Molecular Immunology</i> , <b>2020</b> , 17, 613-620	15.4	910
29	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	402
28	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. <i>Nature Communications</i> , <b>2016</b> , 7, 13473	17.4	77
27	A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. <i>Virology</i> , <b>2016</b> , 499, 375-382	3.6	76
26	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. <i>Cell Research</i> , <b>2020</b> , 30, 932-935	24.7	73
25	Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	72
24	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. <i>Antiviral Research</i> , <b>2020</b> , 179, 104820	10.8	71
23	Vaccines for the prevention against the threat of MERS-CoV. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 1123-34.2	34.2	64
22	A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	62
21	Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	58
20	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , <b>2018</b> , 36, 1853-1862	4.1	44
19	Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. <i>Human Vaccines and Immunotherapeutics</i> , <b>2017</b> , 13, 1615-1624	4.4	43
18	Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. <i>Antiviral Research</i> , <b>2016</b> , 132, 141-8	10.8	43
17	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , <b>2017</b> , 6, e89	18.9	33
16	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. <i>Emerging Microbes and Infections</i> , <b>2018</b> , 7, 7	18.9	30
15	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. <i>Viruses</i> , <b>2019</b> , 11,	6.2	26
14	Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. <i>Biophysical Journal</i> , <b>2021</b> , 120, 1011-1019	2.9	26

13	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. <i>Science China Life Sciences</i> , <b>2017</b> , 60, 1399-1402	8.5	23
12	Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	21
11	Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain. <i>Viruses</i> , <b>2019</b> , 11,	6.2	16
10	Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. <i>Microbes and Infection</i> , <b>2017</b> , 19, 641-647	9.3	12
9	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009897	7.6	11
8	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 29	5.7	10
7	The Development of a Novel Nanobody Therapeutic for SARS-CoV-2 <b>2020</b> ,		10
6	The development of - as anti-SARS-CoV-2 nanobody drug candidates. <i>ELife</i> , <b>2021</b> , 10,	8.9	10
5	The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	6
4	Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	6
3	Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction <b>2020</b> ,		6
2	A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. <i>Cell Reports</i> , <b>2021</b> , 35, 109107	10.6	5
1	Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7,	21	3